Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial

Loïc Renaud; Isabelle Chaillol; Jeau Galtier; Côme Bommier; Benoît Tessoulin; Jean Marc. Schiano De Colella; Thierry Lamy; Cécile Borel; Aapasia Stamatoullas; Anne Clair Gac; Franck Morschhauser; Marc André; Hervé Ghesquières; Alexandra Traverse-Glehen; Olivier Casasnovas; T. Gastine

doi:10.3324/haematol.2026.301194

August 13, 2026HaematologicaOpen Access

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and therapeutic outcomes of brentuximab vedotin consolidation in patients with stage I/II Hodgkin lymphoma who show persistent FDG-PET positivity after two cycles of ABVD chemotherapy.
Conducted the BRAPP2 clinical trial evaluating brentuximab vedotin as a consolidation intervention.
Enrolled patients with stage I/II Hodgkin lymphoma who demonstrated positive FDG-PET scans following two initial cycles of standard ABVD chemotherapy.
The final analysis evaluated the therapeutic impact of brentuximab vedotin consolidation in patients with early-stage Hodgkin lymphoma with interim PET positivity.
Consolidation therapy targeted persistent disease to optimize treatment response and improve outcomes in PET-positive individuals.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Clinical trial reveals outcomes of brentuximab vedotin consolidation in PET-positive early-stage Hodgkin lymphoma, indicating therapeutic efficacy after initial chemotherapy.

Abstract

positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Renaud et al. (2026) studied this question.

synapsesocial.com/papers/6a81796af2fb91fc834ac94d https://doi.org/10.3324/haematol.2026.301194

View Full Paper

Ask AI

Bookmark

Share

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading